Global Drugs for Musculoskeletal Disorders Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Drugs for Musculoskeletal Disorders Market Insights, Forecast to 2034
Musculoskeletal Disorders or MSDs are injuries anddisorders that affect the human body's movement ormusculoskeletal system (i.e. muscles, tendons, ligaments, nerves, discs, blood vessels, etc.). Common MSDs includeCarpal Tunnel Syndrome. Tendonitis. Muscle / Tendon
Global Drugs for Musculoskeletal Disorders market is expected to reach to US$ 86520 million in 2024, with a positive growth of %, compared with US$ 82410 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Drugs for Musculoskeletal Disorders industry is evaluated to reach US$ 110750 million in 2029. The CAGR will be 4.2% during 2024 to 2029.
The Musculoskeletal Disorders Drugs market refers to the pharmaceuticals and medications used for the treatment of disorders and diseases related to the musculoskeletal system, including arthritis, osteoporosis, and musculoskeletal pain. This market encompasses various therapeutic areas such as nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, disease-modifying antirheumatic drugs (DMARDs), and bone health medications. The Musculoskeletal Disorders Drugs market has been witnessing steady growth due to factors such as the aging population, increasing prevalence of musculoskeletal disorders, and advancements in drug development. Key players in the market include pharmaceutical companies, biotechnology firms, and generic drug manufacturers. Geographically, North America holds a significant market share, followed by Europe. However, the market in Asia Pacific is expected to witness substantial growth in the coming years, driven by the rising incidence of musculoskeletal disorders and improving access to healthcare.
Report Covers
This report presents an overview of global Drugs for Musculoskeletal Disorders market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Drugs for Musculoskeletal Disorders market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
AbbVie
Amgen
Johnson & Johnson
Roche
Pfizer Inc
Eli Lilly
Merck
Novartis
UCB
Segment by Type
OTC
Rx Drugs
Hospital
Retail Pharmacy
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
UK
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Drugs for Musculoskeletal Disorders plant distribution, commercial date of Drugs for Musculoskeletal Disorders, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Drugs for Musculoskeletal Disorders introduction, etc. Drugs for Musculoskeletal Disorders Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports’s Conclusions of Drugs for Musculoskeletal Disorders
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Global Drugs for Musculoskeletal Disorders market is expected to reach to US$ 86520 million in 2024, with a positive growth of %, compared with US$ 82410 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Drugs for Musculoskeletal Disorders industry is evaluated to reach US$ 110750 million in 2029. The CAGR will be 4.2% during 2024 to 2029.
The Musculoskeletal Disorders Drugs market refers to the pharmaceuticals and medications used for the treatment of disorders and diseases related to the musculoskeletal system, including arthritis, osteoporosis, and musculoskeletal pain. This market encompasses various therapeutic areas such as nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, disease-modifying antirheumatic drugs (DMARDs), and bone health medications. The Musculoskeletal Disorders Drugs market has been witnessing steady growth due to factors such as the aging population, increasing prevalence of musculoskeletal disorders, and advancements in drug development. Key players in the market include pharmaceutical companies, biotechnology firms, and generic drug manufacturers. Geographically, North America holds a significant market share, followed by Europe. However, the market in Asia Pacific is expected to witness substantial growth in the coming years, driven by the rising incidence of musculoskeletal disorders and improving access to healthcare.
Report Covers
This report presents an overview of global Drugs for Musculoskeletal Disorders market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Drugs for Musculoskeletal Disorders market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
AbbVie
Amgen
Johnson & Johnson
Roche
Pfizer Inc
Eli Lilly
Merck
Novartis
UCB
Segment by Type
OTC
Rx Drugs
Segment by Application
Hospital
Retail Pharmacy
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
UK
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Drugs for Musculoskeletal Disorders plant distribution, commercial date of Drugs for Musculoskeletal Disorders, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Drugs for Musculoskeletal Disorders introduction, etc. Drugs for Musculoskeletal Disorders Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports’s Conclusions of Drugs for Musculoskeletal Disorders
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices